However, the combination treatment greatly induced BAX/BAK activation and cytochrome C release (Fig. 3D), supporting the highly synergistic effect of the combination in TP53-deficient AML cells based on this mechanism. This evidence concerns the gene BAK1 and acute myeloid leukemia.